DeepHealth, a wholly owned subsidiary of RadNet, Inc. (RDNT), has introduced an expanded portfolio of imaging informatics and clinical AI solutions at the Radiological Society of North America (RSNA) 2025 meeting in Chicago.
The new offerings aim to unify clinical and operational intelligence, accelerate adoption of AI-powered imaging and advanced population health.
The portfolio spans detection, assessment and monitoring, remote scanning, image management and interpretation, center operations, and AI orchestration. Anchored by DeepHealth OS, a cloud-native operating system, the solutions are designed to simplify deployment, improve workflow efficiency, and enhance patient access.
Key product suites include:
- Diagnostic Suite 1- Cloud-first enterprise image management and interpretation tools with ultra-fast streaming, AI-powered reporting, and advanced visualization.
- TechLive - A multimodality, vendor-agnostic remote imaging and radiology management solution, with FDA 510(k) clearance, already connecting 400+ scanners and reducing MR room closure by 42%. The platform is also expanding through GE HealthCare collaboration and continues rollout with GE HealthCare ultrasound products and Alpha RT remote scanning technology.
- Operations Suite - A cloud-first platform unifying scheduling, billing, analytics, and patient communication, with agentic AI to reduce administrative burden. Deployment is underway across RadNet and customer sites, transitioning from legacy RIS systems.
- DeepHealth Breast Suite - FDA-cleared applications for breast cancer detection, risk assessment, density analysis, and workflow tools, supporting over 10 million mammograms annually. A recent Nature Health study showed a 21% increase in detection rates across 579,000 women. The suite is being integrated into GE HealthCare mammography systems as a part of the expanded collaboration.
- DeepHealth Thyroid Suite — AI-powered thyroid ultrasonic application automating nodule detection and characterization, with >94% acceptance of AI measurements in real-world deployment. This suite is also being integrated into GE HealthCare ultrasound systems globally.
- DeepHealth Neuro Suite — FDA-cleared tools for white matter hyperintensity (WMH) detection and volumetric brain analysis, supporting proactive care.
- DeepHealth Chest Suite — Al- driven pulmonary nodule detection and tracking, enabling earlier lung cancer diagnosis. UK data show 76% of cancers detected at earlier stages versus 29% historically. Applications within the Chest Suite are cleared in Europe and the UK and are currently US 510 (k)-pending, with plans to expand availability to the US clinical sites.
- DeepHealth Prostate Suite — Streamlined prostate MRI interpretation and biopsy planning workflows, integrating lesion detection, risk classification, and PI-RADS-compliant reporting. The suite is also being evaluated in the UK TRANSFORM prostate screening trial.
- AI Studio — An orchestration platform integrating 140+ AI algorithms from 75+ vendors, with governance tools for monitoring and drift management.
DeepHealth's expanded portfolio is already deployed across RadNet's 407 imaging centers and other customer sites worldwide, with more than 5,000 radiologists leveraging its solutions. The company emphasizes that these innovations are designed to shift disease stages, expand patient access, and elevate care teams.
DeepHealth will also present real-world evidence from AI deployments in clinical imaging and operational workflows, along with live demonstrations at RSNA 2025, including interactive sessions.
RDNT closed Friday's trading session unchanged at $82.79 before slipping to $82.24 in overnight trading, down 0.66%. Trading volume came in at roughly 559k shares versus an average volume of over 723k shares. Over the past 12 months the stock has traded between $45 to $85.84.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.